PCRX (Pacira BioSciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PCRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | JONATHAN SLONIN | Chief Medical Officer | Sell | — | — |
| 2026-06-12 | LAUREN RIKER | Senior Vice President, Finance | Sell | — | — |
| 2026-06-12 | MARCELO BIGAL | Director | A | — | — |
| 2026-06-12 | MICHAEL J. YANG | Director | A | — | — |
| 2026-06-12 | Mark Froimson | Director | A | — | — |
| 2026-06-12 | Alethia Young | Director | A | — | — |
| 2026-06-12 | Laura Brege | Director | A | — | — |
| 2026-06-12 | Samit Hirawat | Director | A | — | — |
| 2026-06-12 | CHRISTOPHER CHRISTIE | Director | A | — | — |
| 2026-06-12 | THOMAS G WIGGANS | Director | A | — | — |
| 2026-06-05 | JONATHAN SLONIN | Chief Medical Officer | F | — | — |
| 2026-06-05 | LAUREN RIKER | Senior Vice President, Finance | F | — | — |
| 2026-06-05 | KRISTEN WILLIAMS | Chief Administrative Officer | MIXED | — | — |
| 2026-04-24 | Shawn Cross | Chief Financial Officer | MIXED | — | — |
| 2026-04-22 | Shawn Cross | Chief Financial Officer | MIXED | — | — |
| 2026-03-19 | Mark A. Kronenfeld | Director | A | — | — |
| 2026-03-19 | JONATHAN SLONIN | Chief Medical Officer | Sell | — | — |
| 2026-03-19 | Mark Froimson | Director | Sell | — | — |
| 2026-02-13 | Frank D. Lee | Chief Executive Officer | A | — | — |
| 2026-02-13 | LAUREN RIKER | Senior Vice President, Finance | A | — | — |
| 2026-02-13 | KRISTEN WILLIAMS | Chief Administrative Officer | A | — | — |
| 2026-02-13 | JONATHAN SLONIN | Chief Medical Officer | A | — | — |
| 2026-02-13 | Shawn Cross | Chief Financial Officer | A | — | — |
| 2026-02-13 | Brendan Teehan | Chief Commercial Officer | A | — | — |
| 2026-02-03 | KRISTEN WILLIAMS | Chief Administrative Officer | MIXED | — | — |
| 2026-02-03 | Frank D. Lee | Chief Executive Officer | F | — | — |
| 2026-02-03 | JONATHAN SLONIN | Chief Medical Officer | F | — | — |
| 2026-02-03 | Brendan Teehan | Chief Commercial Officer | F | — | — |
| 2026-02-03 | LAUREN RIKER | Senior Vice President, Finance | MIXED | — | — |
| 2026-01-29 | Samit Hirawat | Director | A | — | — |
| 2026-01-06 | Frank D. Lee | Chief Executive Officer | F | — | — |
| 2026-01-06 | JONATHAN SLONIN | Chief Medical Officer | F | — | — |
| 2026-01-06 | LAUREN RIKER | Senior Vice President, Finance | MIXED | — | — |
| 2026-01-06 | Brendan Teehan | Chief Commercial Officer | A | — | — |
| 2025-12-11 | Shawn Cross | Chief Financial Officer | MIXED | — | — |
| 2025-11-19 | JONATHAN SLONIN | Chief Medical Officer | Sell | — | — |
| 2025-11-13 | Shawn Cross | Chief Financial Officer | Sell | — | — |
| 2025-11-03 | Shawn Cross | Chief Financial Officer | F | — | — |
| 2025-09-08 | Abraham Ceesay | Director | Sell | — | — |
| 2025-08-11 | MARCELO BIGAL | Director | Sell | — | — |
| 2025-08-04 | JONATHAN SLONIN | Chief Medical Officer | F | — | — |
| 2025-06-13 | MICHAEL J. YANG | Director | A | — | — |
| 2025-06-13 | MARCELO BIGAL | Director | A | — | — |
| 2025-06-13 | CHRISTOPHER CHRISTIE | Director | A | — | — |
| 2025-06-13 | Mark A. Kronenfeld | Director | A | — | — |
| 2025-06-13 | Alethia Young | Director | A | — | — |
| 2025-06-13 | Laura Brege | Director | A | — | — |
| 2025-06-13 | Mark Froimson | Director | A | — | — |
| 2025-06-13 | Abraham Ceesay | Director | A | — | — |
| 2025-06-05 | LAUREN RIKER | Senior Vice President, Finance | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,828,941 | — |
| — | 10%+ Owner | 2,790,479 | — |
| — | 10%+ Owner | 2,790,479 | — |
| — | 10%+ Owner | 2,588,200 | — |
| — | 10%+ Owner | 2,561,084 | — |
| — | 10%+ Owner | 2,546,100 | — |
| — | 10%+ Owner | 2,509,100 | — |
| — | 10%+ Owner | 2,293,227 | — |
| — | 10%+ Owner | 2,233,993 | — |
| — | Director | 844,566 | — |
| — | Chief Executive Officer | 660,830 | — |
| — | Director | 500,672 | — |
| — | Director | 451,324 | — |
| — | Chief Medical Officer | 216,383 | — |
| — | CEO and Chairman | 205,077 | — |
| — | Chief Administrative Officer | 167,062 | — |
| — | Chief Operating Officer | 115,443 | — |
| — | Chief Financial Officer | 105,341 | — |
| — | Chief Commercial Officer | 100,934 | — |
| — | Director | 70,399 | — |
| — | Senior Vice President, Finance | 62,284 | — |
| — | 10%+ Owner | 58,411 | — |
| — | Chief Medical Officer | 52,440 | — |
| — | Chief Financial Officer | 51,867 | — |
| — | 10%+ Owner | 48,657 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCRX quote page; the site-wide leaderboard is on the insider transactions hub.